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23 ABSTRACT
24 Objectives: The second generation antipsychotic quetiapine has been demonstrated to undergo 
25 gestation related changes in pharmacokinetics. This study applied pharmacokinetic modelling 
26 principles to investigate the mechanism of these changes and to propose new dosing strategies 
27 to counteract these changes
28 Methods: A pharmacokinetic modelling approach was implemented using virtual population 
29 groups.  Changes in quetiapine trough plasma concentration during gestation were quantified 
30 across all trimesters and dose adjustment strategies were applied to counteract these changes 
31 by targeting a therapeutic range of 50-500 ng/mL throughout gestation 
32 Findings: The application of the model during gestation predicted a decrease in trough 
33 concentration. A maximum decrease of 58 % was predicted during trimester 2, and being 
34 associated with a statistically significant decrease in oral clearance at gestation week 25, 204 
35 L/h ± 100.8 L/h compared to non-pregnant subjects, 121.9 L/h ± 51.8 L/h.  A dosing 
36 optimisation strategy identified that dose increases to 500-700 mg twice daily would result in 
37 32-55 % of subjects possessing trough concentration in excess of 50 ng/mL.
38 Conclusions: Quetiapine doses in pregnancy should be increased to 500-700 mg twice daily to 
39 counteract a concomitant increase in metabolic clearance, increase in volume of distribution 
40 and decrease in plasma protein binding.
41
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44 1. INTRODUCTION
45 Quetiapine is a second generation antipsychotic that was first approved by the US Food and 
46 Drug Administration (FDA) in 1997 for the management of schizophrenia in both adults and 
47 adolescents in addition to a range of other psychiatric disorders [1, 2].  
48 Several reports have highlighted that quetiapine is the most commonly prescribed atypical 
49 antipsychotic in women of childbearing age [3-5].  A key advantage of quetiapine over other 
50 atypical antipsychotics is that it is unlikely to be associated with extrapyramidal symptoms and 
51 is prolactin (PRL)-sparing but is associated with weight gain [6].  
52 However, the use of pharmacological interventions for psychiatric disorders during pregnancy 
53 is particularly challenging, given the need to balance stabilisation of maternal mental state with 
54 the potential teratogenic effects of the prescribed drug.  Often, this results in the cessation of 
55 treatment during the gestational period, particularly in trimester 1 [7].
56 In the wider context of pregnancy, approximately 15 % of women have some form of 
57 psychiatric illness with up to 13 % of women taking prescribed psychotropic pharmacological 
58 interventions [8, 9]. Clinicians are likely to be faced with the possibility of treatment (or not) 
59 within the perinatal setting. However, clinical studies have demonstrated that pregnancy should 
60 be considered as a ‘high-risk’ period for relapse in the context of a discontinuation of any 
61 maintenance treatment options [10-14].  This is particularly important given that recent reports 
62 in the UK have suggested that 1 in 25 women (aged 20-35 years) who die by suicide, do so 
63 during the perinatal periods (conception-pregnancy and post-natal) [15].  And further, that poor 
64 mental health during gestation is highly correlated with poor mental health postnatally [14]. 
65 Mounting evidence supports the notion that cessation of therapy during pregnancy may be 
66 detrimental to the mother for some antipsychotics, a choice which requires consideration of the 
67 risks and benefits of pharmacological interventions during gestation [7, 16, 17].  Although the 
68 risks of antipsychotic use during pregnancy may be outweighed by the clinical benefits, 
69 gestation brings about significant changes in the physiology of the mother which can have 
70 drastic changes on the pharmacokinetics of drugs administered during pregnancy.  Quetiapine 
71 is primarily metabolised by the phase-1 Cytochrome P450 enzyme CYP 3A4 [18], and 
72 gestation can result in a significant increase in the expression of CYP3A4 [19-21] by between 
73 25-40 % [22], which would enhance quetiapine metabolic clearance and hence results in a net 
74 reduction in quetiapine plasma concentrations.  An obvious change occurs in body composition 
75 with a 40-50 % increase in plasma volume [23, 24] throughout gestation along with a 
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76 concomitant increase in body fat, approximately 4 kg, resulting in alterations of the volume of 
77 distribution of hydrophilic and lipophilic drugs during gestation which would generally reduce 
78 plasma drug concentration  In addition, decreases in the plasma-proteins albumin and alpha-1-
79 acidic glycoprotein will in turn increase the free drug fraction and directly influence the volume 
80 of distribution [25-27].
81 In a recent retrospective study, the plasma levels of a range of antipsychotics were analysed 
82 during gestation and it was identified that significant decreases in serum levels were evident, 
83 particularly for quetiapine, which decreased by up to 70 % in trimester 3 [28].
84 At present, there are no well-controlled or reliable studies of quetiapine use during pregnancy, 
85 and because of this reason the FDA have classified quetiapine as a category C drug, suggesting 
86 it should be used during pregnancy only if the benefits to the mother outweigh any risks to the 
87 patient.  However, the US Office of Paediatric Therapeutics conducted a review of 220 adverse 
88 reports associated with quetiapine, which were submitted to the FDA adverse event reporting 
89 systems and identified that there doesn’t seem to be a risk of congenital anomalies but 
90 acknowledge the limited nature of the data reported [29].   Further, the clinical toxicology 
91 database TOXBASE® (https://www.toxbase.org) from the National Poisons Information 
92 Service Unit [30], has provided guidance for the use of quetiapine during gestation and does 
93 not advocate its cessation necessarily, rather places emphasis on the consideration of the risk 
94 of relapse on cessation compared to the benefits to the mother and child during gestation.
95 We have, for the first time, applied the principles of mechanistic pharmacokinetic modelling 
96 and virtual clinical trials to better elucidate the causative effects of this decrease in plasma 
97 quetiapine levels during gestation, to provide a clinically relevant dosing adjustment strategy 
98 that could be implemented to maintain plasma quetiapine levels during gestation.  
99 The objectives of this study were to: (i) develop a robust and validated pharmacokinetic model 
100 for quetiapine; (ii) identify a suitable therapeutic window for quetiapine and (iii) explore the 
101 impact of gestation on quetiapine plasma levels and address any alterations with clinically 
102 appropriate dose adjustments.  
103
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104 2. METHODS
105 Simulations were performed using the virtual clinical trial simulator Simcyp (Simcyp® Ltd, a 
106 Certara company, Sheffield, UK, Version 16).  The ‘Healthy Volunteer’ population group was 
107 used for ‘non-pregnant’ females and the ‘Pregnancy’ population group utilised for all 
108 ‘pregnancy’ studies.  The latter population group included necessary gestational dependant 
109 changes in physiology, such as blood volume and organ/tissue perfusion and enzyme/protein 
110 expression, which are thought to play a role in altering the pharmacokinetics of drugs [31-34].  
111 A 4-stage modelling approach was implemented.  A previously validated model of quetiapine 
112 [35] was utilised with adaptations through the inclusion of CYP3A5 metabolic clearance 
113 pathway [36, 37].
114
115 2.1 Step 1: Validation of quetiapine 
116 In order to implement a pregnancy model within Simcyp the previously validated quetiapine 
117 model [35] required modification as the model primarily implemented a minimal-PBPK model, 
118 which does not allow consideration of a distinct foetal/placental tissue compartment and 
119 physiological alterations in other maternal tissues during gestation.  For simulations in pregnant 
120 subjects, a full-PBPK distribution model was required and therefore tissue-partition coefficient 
121 (Kp) estimates were calculated using the Rogers and Rowland approach [38, 39].  These were 
122 then parameter estimated (using a Weighted Least Square (WLS) method and the Nelder-Mead 
123 minimisation approach) through the optimisation of a tissue partition coefficient scalar, Kpscalar, 
124 using a total of 3 single dose studies and 1 multi-dose study: (i) 12 men (24-42 years old) dosed 
125 a single oral dose of 25 mg [40]; (ii) 15 men and 3 women (29-63 years old) dosed at 25 mg 
126 twice daily on day 1, 50 mg twice daily on day 2, 100 mg twice daily on day 3, 200 mg twice 
127 daily on day 4 and 300 mg twice daily on day 5 until day 10 [40]; (iii) 10 men (35-55 years 
128 old) dosed at 25 mg three times daily (TID) (6 am, 2 pm and 10 pm) on day 1 and dose escalated 
129 to 50 mg TID on day 2, 75 mg TID on day 3, 100 mg TID on day 4 and by 50 mg increments 
130 daily until 250 mg TID on days 7 and 8 [41]; (iv) 11 men and 2 women (19-58 years) dosed at 
131 25 mg twice daily (BD) on day 1 and dose escalated to 50 mg BD on day 2, 75 mg BD on day 
132 3, 100 mg BD on day 4 and by 50 mg increments daily until 300 mg BD on 8 until day 21 [42]. 
133
134 Model simulations were run to match the reported age range and patient number reported by 
135 each study.  However, in the absence of this information, a default trial size of 100 subjects 
136 (10x10 design) aged 20-40 years old was used.
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137 Quetiapine model parameters can be found in Supplementary Materials: Section 1.
138
139
140 2.2 Step 2: Validation of CYP3A5 metabolic clearance modification
141 To further validate the appropriateness of modifications made to the CYP3A5 intrinsic 
142 clearance [37], three retrospective clinical drug-drug interactions studies were used to further 
143 validate the model and consisted of: (i) ketoconazole dosed alone for days 1 to 3 and in 
144 conjunction with quetiapine on day 4 [40]; (ii) quetiapine dose escalated to 300 mg twice daily 
145 by day 5 and maintained for 34 days.  Thereafter  carbamazepine initiated with a 200-mg dose 
146 on the evening of day 9, followed by 200 mg twice daily on days 10- 12, and increased to 200 
147 mg three times daily from days 13-33 with a final dose on the morning of day 34 [40] and (iii) 
148 quetiapine dose escalated from 25 to 250 mg three times daily by day 10 and maintained until 
149 day 23 with phenytoin administered at 100 mg three times daily on days 13-33 in conjunction 
150 with quetiapine [41]. 
151 Where possible, trial design and sampling duration was replicated from the original studies.
152
153 2.3 Step 3: Validation during gestation
154 A recent report by Westin et al [28] retrospectively collated serum level of antipsychotics 
155 before, during and after pregnancy.  Data for quetiapine consisted of 66 measurements during 
156 pregnancy, 11 during the first 12 weeks following pregnancy and 144 at baseline, from 33 
157 women.  Subjects were stabilised on 400 mg/daily. This data was extracted, pooled and utilised 
158 as ‘observed’ data for validation purposes. 
159 In simulating quetiapine pharmacokinetics during gestation, a 38-week trial design was 
160 utilised, with simulations conducted using a 10x10 trial design with dosing adjusted on a daily 
161 basis by 50 mg/day to 200 mg twice daily for all subjects.
162 For all dosing approaches in pregnancy, unless otherwise stated, the pre-dose (trough) plasma 
163 concentration was ascertained 10 hours following each dose. For assessment of plasma 
164 concentration, all concentrations were dose adjusted to the defined daily dose (DDD), whereby 
165 the simulated plasma concentration was divided by the daily dose and subsequently multiplied 
166 by the DDD (the average maintenance dose per day for its main indication in adults)[43].
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167 For comparison, the trial design was also replicated for Healthy Volunteer population of non-
168 pregnant females dosed under the same dosing strategy.
169 2.4 Step 4: Dose adjustment during gestation
170 Limited data currently exists purporting to show a relationship between plasma quetiapine 
171 levels and clinical responses and these have recently been summarised in a review by Mauri et 
172 al (2018) [44].  Further, a suggested therapeutic window of between 100-500 ng/mL has been 
173 proposed by the Arbeitsgemeinschaft für Neuropsychopharmakologie und 
174 Pharmakopsychiatrie (AGNP) [45] and this was adopted as the potential therapeutic window. 
175 However, the region of 50-100 ng/mL was also considered as a ‘borderline’ range, given that 
176 doses in the range of 150-800 mg daily can yield mean trough concentrations in the range of 
177 27-387 ng/mL [46-50]. Although the  FDA advocated maximum recommended dose is 800 mg 
178 daily [51], a number of studies have assessed the safety of higher doses in non-pregnant 
179 subjects to a maximum of 1400 mg daily [52-54] with no significant safety concerns.
180 In a recent case report the need for dose adjustment to be made during pregnancy for women 
181 with bipolar disorder was highlighted [55], with dose escalation by up to an additional 350 
182 mg/daily in some cases to maintain symptom control during gestation.   Further, previous 
183 reports of foetal exposure of quetiapine have occurred at dose ranges of 300-600 mg/day during 
184 gestation with no harmful effects on the new-born [56-59].  Interestingly a dose of 1200 mg/day 
185 was also used at mid-pregnancy (21 weeks gestation) as identified in a case report by Çabuk 
186 [60], which resulted in a normal birth.  Although mainly case reports, these serve as useful 
187 guidance for potential dose escalation strategies required. 
188
189 In order to assess the requirement for dose optimisation, simulations were conducted with 100 
190 subjects (10x10 design) aged 20-30 years. Simulations were commenced on day 1 of gestation 
191 and terminated on day 1 of week 39. Dose escalation studies included ‘baseline’ simulations 
192 of 200 mg twice daily and subsequently by 50 mg increments every 3 days to a maximum of 
193 700 mg twice daily.  Data was sampled on the final 24 hour period of every 5th week up to and 
194 including week 38.
195 2.5 Predictive Performance
196 For all simulations in steps 1-3, a prediction of a pharmacokinetic metric to within two-fold 
197 (0.5-2.0 fold) of published clinical data was generally accepted as part of the ‘optimal’ 
198 predictive performance [61-63].
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199 2.7 Visual Predictive Checks
200 Model predictions in step 1-3 were compared to clinical studies using a visual predictive 
201 checking (VPC) strategy [64]. In this approach, the predicted mean/median and 5th and 95th 
202 percentiles of the concentration–time profiles (generated from Simcyp®) were compared 
203 against the observed data for any validation data sets.  The prediction was assumed to be valid 
204 when the predicted data points overlapped with the observed data sets.
205 2.8 Data and statistical analysis
206 All observed data obtained from clinical studies were extracted using WebPlotDigitizer v.3.10 
207 (http://arohatgi.info/WebPlotDigitizer/). Statistical analysis was conducted using a non-
208 parametric Kruskal-Wallis with a Dunn’s multiple comparison post-hoc test. Statistical 
209 significance was confirmed where a P < 0.05 was computed. 
210
211 3. RESULTS
212 3.1 Step 1: Validation of quetiapine 
213 A previously published quetiapine model was adapted with the incorporation of a full-PBPK 
214 model in order to predict tissue partition coefficient and enable a full mechanistic model to be 
215 utilised, in addition to the incorporation of a CYP3A5 metabolic pathway.  The adapted file 
216 was validated against a range of published clinical studies using the Simcyp Healthy Volunteer 
217 population group (See section 2.1).  For all single and multi-dose studies (Supplementary 
218 Materials: Section 2 Figure S1) along with drug-drug interactions simulations (Supplementary 
219 Materials: Section 2 Figure S2), the simulated plasma concentration-time profiles were 
220 successfully predicted to within the observed range for each study and model-predicted tmax, 
221 Cmax, and AUC were predicted to within 2-fold of the reported parameters for each study, 
222 confirming successful validation (Table 1). 
223
224 When compared to non-pregnant females (baseline), the median steady-state trough plasma 
225 concentrations of quetiapine decrease during gestation (Figure 1) with a statistically significant 
226 difference between baseline and the mid-point of trimesters 1-3 (final day of weeks 6, 20 and 
227 32 respectively) (P < 0.001, Dunn’s post-hoc comparison) (Table 2).  During gestation the 
228 predicted median plasma concentration decreased by between 52-58 %.
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229 The reduced plasma concentration during gestation was associated with a concomitant increase 
230 in oral clearance (CL/F) which was significantly different from baseline from gestational week 
231 10 onwards (P < 0.05, Dunn’s post-hoc comparison) and reached a maximum at GW 25, 204 
232 L/h ± 100.8 L/h compared to baseline, 121.9 L/h ± 51.8 L/h (Figure 2A).  Further, changes in 
233 volume of distribution are significant from week 25 onwards, rising from a baseline of 329.2 
234 L ± 71 L to 368.4 L ± 71.3 L at GW 38 (Figure 2B).  A statistically significant increase in 
235 unbound fraction was also noted from GW 10 onwards and with fuplasma being 21-26 % greater 
236 from weeks 30 onwards (fuplasma = 0.0218-0.0225)  (Figure 2C).
237 Understanding the importance of maternal physiological changes during gestation on 
238 quetiapine pharmacokinetics is clearly multifaceted.  Therefore we conducted a sensitivity 
239 analysis using a non-pregnant and pregnant (GW: 10, 20 and 30) female population group 
240 where we directly examined the impact of variation in the CYP 3A4 hepatic abundance (137 
241 pmol/mg protein to 180 pmol/mg protein, representing a 30 % increase from baseline levels) 
242 and Kp scalar (1 to 3, representing a Vss range of 3.8 L/kg to 11 L/kg; implemented using 
243 Simcyp estimated Kp’s) (Figure 3).  When considering non-pregnant subjects, the trough serum 
244 concentrations are largely sensitive to changes in both Vss (Kp scalar) and CYP 3A4 
245 abundance, although the former has a greater influence.   Conceptually, an increase in Vss 
246 would result in a net reduction in peak (Cmax) plasma concentrations with a concomitant shift 
247 in the distribution and elimination phases of the drug.  However, this shift in the latter phases 
248 of the plasma concentration-time profile would result in a net increase in the trough plasma 
249 concentration (Cmin) (Figure 3A).  At a fixed hepatic abundance, for example the default hepatic 
250 abundance in healthy (non-pregnant) subjects of 137 pmol/mg protein, any increase in Kp 
251 scalar (and hence increased in Vss) would increase the Cmin (Figure 3B).  However, during 
252 gestation the increase in CYP 3A4 hepatic abundance would negate the impact of an increase 
253 in Vss on the Cmin, and result in a net reduction in trough plasma concentration (Figure 3).  
254
255 3.4 Step 4: Dose adjustment during gestation
256 In order to address the reduced plasma concentration during gestation, a dose escalation 
257 strategy was explored, whereby doses were increased by 50 mg increments every 3 days to a 
258 maximum of 500 mg twice daily, from a baseline dose of 200 mg twice daily.
259 As expected, the dose increase during gestation resulted in an increase in median plasma 
260 concentration (Figure 4).  A dose increase of 300 mg (i.e. 500 mg twice daily) was required to 
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261 yield > 70 % of subjects with a trough plasma concentration in excess of 50 ng/mL throughout 
262 gestation (Table 3). However, a dose increase of 500 mg (i.e. 700 mg twice daily) was required 
263 to ensure >60 % of subjects possessed a trough plasma concentration in excess of 100 ng/mL 




268 The decision to use any pharmacological intervention during pregnancy is challenging 
269 for the mother in addition to the prescriber and requires clear knowledge of potential harmful 
270 effects on the developing foetus and risks such as the development of gestational diabetes.  
271 However, the choice to continue treatment or not, can be overshadowed by the clinical need 
272 for therapy during gestation, and the potential consequences of withdrawing treatment [13, 14].
273 Gestation brings about clear physiological changes which are known to alter the 
274 pharmacokinetic profile of drugs. However, the consequences of such changes are often 
275 difficult to ascertain clinically in a controlled trial for obvious ethical reasons.  However, in an 
276 attempt to assess the potential impact of pregnancy on antipsychotic therapy, the use of robust 
277 mechanistic pharmacokinetic models allows for a prospective assessment of the potential 
278 impact and changes in plasma concentrations.
279 A recent report by Westin et al [28] examined the plasma concentrations of antipsychotics 
280 during gestation from retrospective analysis of therapeutic drug monitoring (TDM) clinical 
281 data from Norway.  They identified that quetiapine and apriprazole exhibited a significant 
282 decrease in plasma concentrations during gestation, by between 50-80 % by trimester 3.  
283 Further decrease were noted for perphenazine and haloperidol, but this was limited by the 
284 number of TDM measurements available.   Nevertheless, the potential for gestation-related 
285 decrease in antipsychotic plasma concentrations was noted.
286   
287 Given the lack of more detailed clinical studies examining these phenomena, this study applied 
288 the principle of pharmacokinetic modelling to prospectively assess the use of quetiapine in 
289 pregnancy population groups and attempted to relate changes in plasma concentrations during 
290 gestation to a potential therapeutic window region.  The Simcyp Pregnancy PBPK model has 
291 been utilised by our group [65] and others [32, 33] for prediction of the impact of changes in 
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292 plasma concentrations associated with gestation, however this is the first time it has been 
293 utilised in the context of quetiapine.
294 The model developed incorporated adaptations to two existing quetiapine PBPK models [35, 
295 37] and was validated against single and multiple dose studies (Supplementary Materials: 
296 Section 2 Figure S2).  The resulting predictions were within 2-fold of those reported along with 
297 appropriate VPC confirming population level variability in plasma concentrations were 
298 appropriately predicted in relation to the clinically reports variability.  Further, the inclusion of 
299 the revisions to the CYP 3A5 component [37] were able to recapitulate the impact of 
300 appropriate DDIs on plasma concentrations (Supplementary Materials: Section 2 Figure S3).
301 To our knowledge, Westin et al [28] is the only publication (to date) containing quetiapine 
302 plasma concentrations throughout gestation and this was used as the basis for validating the 
303 quetiapine pregnancy PBPK model.  Simulations were run for the entire gestation period (38 
304 weeks) with sampling of the first day on each week for every 5 weeks reported (Figure 1).    For 
305 non-pregnant subjects (baseline), model predicted plasma concentrations (54.59 ng/mL ± 26.98 
306 ng/mL) were within 2-fold of those reported by Westin et al [28] (75.6 ng/mL) (Table 2), whilst 
307 also spanning across a similar range. Westin et al [28] reported a 22 %, 57 % and 76 % decrease 
308 in mean plasma concentration at for trimesters 1, 2 and 3 respectively.  Using the PBPK model 
309 we demonstrated a similar decrease of 52-58 % across gestation, although the predicted 
310 decrease for trimester 1 was greater than that reported [28].  Nonetheless, the trend throughout 
311 gestation for a decrease in plasma concentration was similar, and represents an important 
312 phenomenon, which is likely to result in sub-therapeutic plasma concentrations if we assume a 
313 lower limit of the therapeutic window to be 100 ng/mL. 
314 In order to identify the cause of this change in plasma concentrations during gestation, we first 
315 examined the impact of changes in CYP 3A4 expression on oral clearance.  Previous reports 
316 have identified significant alterations in CYP 3A4 expression with gestation, and given the 
317 major contribution of CYP 3A4 to overall CYP-mediated metabolic clearance, > 90 % [18, 40], 
318 this is a key component for the overall pharmacokinetics of quetiapine.  The impact of gestation 
319 on the metabolic clearance of CYP 3A4 substrates has been previously reported as leading to 
320 an approximate 25-40 % increase in the clearance [22, 66]
321 An increase in oral clearance was observed at week 5 for pregnant subjects, (149.5 L/h ± 75.17 
322 L/h) compared to baseline (non-pregnant) subjects at the same time point (121.9 L/h ± 51.53 
323 L/h) (Figure 2A), however this was not statistically significant.  From week 10 to 38, the oral 
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324 clearance increased, compared to baseline subjects, with week 20 demonstrating the greatest 
325 difference (184.1 L/h ± 100.5 L/h) (P < 0.001) (Figure 2A).  Further, an increase in total body 
326 water and plasma volume that occur throughout gestation did not have a significant impact on 
327 the Vss until week 25, where Vss reached 357.2 L ± 71.9 L, compared to 329.2 L ± 71 L for 
328 non-pregnant subjects (Figure 2B).  Previous reports have demonstrated Vss can range from 
329 400-800 L for non-pregnant subjects, for both single and multidose studies [67-69].  The 
330 approximate 10 % increase in Vss during gestation, although significant, may only contribute 
331 a minor role to the change in trough concentration. A net increase in the unbound fraction 
332 plasma (fuplasma) (21-26 % greater from weeks 30 onwards) was also simulated when comparing 
333 baseline (Figure 2C).  This net increase would result in an increase in circulating unbound drug, 
334 resulting in an increase in the volume of distribution whilst also partly contributing to 
335 potentially enhanced exposure of drug to the liver.  However, the conceptualisation of this 
336 effect on trough levels is multifaceted. The gestation-mediated increase in CYP 3A4 hepatic 
337 abundance negates the impact of an increase in the volume of distribution and results in a net 
338 reduction in trough plasma concentration (Figure 3).  
339 To address the reduction in quetiapine plasma concentrations during gestation, we assessed the 
340 impact of dose escalation which was required to recapitulate trough plasma concentrations to 
341 within the therapeutic window.  Because of the uncertainty surrounding the precise range of 
342 the therapeutic window, a lower limit was set at either 50 ng/mL or 100 ng/mL (see section 
343 2.4).  In non-pregnant subjects, a 200 mg twice daily dose yielded a median steady-state trough 
344 concentration of 59.47 ng/mL ± 26.98 ng/mL, which significantly decreased during gestation 
345 to a minimum of 30.55 ng/mL at GW 20 (P < 0.001, Dunn’s post-hoc comparison) (Figure 4) 
346 (Supplementary Materials: Section 3 Table S2).  Further, this resulted in a significant number 
347 of subjects failing to attain the lower therapeutic window, < 35 % of subjects for 50 ng/mL 
348 (Table 4) and < 15 % of subjects for 100 ng/mL (Table 3).   This trend broadly concurs with 
349 those reported by Westin et al [28], where the majority of reported plasma concentrations 
350 during gestation fell below the 50 ng/mL lower limit (Figure 1), highlighting the need to 
351 consider dose escalation during gestation.
352 Although a dose increase to 500 mg twice daily would be sufficient to ensure 30-50 % of 
353 subjects attained the upper therapeutic window of 100 ng/mL (Table 3), a dose increase to 700 
354 mg twice daily was identified as satisfying the requirement to attain both the 50 ng/mL and 100 
355 ng/mL lower windows (Figure 4), with attainment of > 95 % and > 62 % of subjects 
356 respectively.  Whilst trials have suggested an upper dose of 800 mg/day [2, 70, 71], higher 
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357 doses of between 800-2000 mg/day [72-76] have been reported to be tolerated in acute and 
358 maintenance therapy.  Further, sparse case reports are available of significantly higher 
359 overdoses of least 20-24 g being ingested with little acute effects [77, 78].
360 The increase in dose may warrant closer monitoring with possible monthly clinical evaluations 
361 during gestation.  This would allow for assessment for any worsening of mood disorder 
362 symptoms during administration of higher doses of quetiapine.  This can consist of trained 
363 clinician administered structured interviews (e.g. SIGH-ADS[79] or MRS[80]).  Furthermore, 
364 recommendations from the Royal College of Psychiatrists Consensus Statement [81] advocated 
365 the use of scales such as the Brief Psychiatric Rating Scale (BPRS)[82] and Health of the 
366 Nation Outcome Scales (HoNOS)[83] in addition to assessing adverse effects through the 
367 Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS)[84], for high dose 
368 antipsychotic use.
369 Given that the metabolic clearance of quetiapine is mediated largely by CYP3A4 [18], and 
370 gestation can result in a significant increase in the expression of CYP3A4 [19-21], an increase 
371 in dose would be necessary during gestation to ensure trough plasma concentrations are in 
372 excess of the lower therapeutic window. 
373 Although limited studies have examined the need for a dose increase during pregnancy, those 
374 that have reported this have shown that a 2-to-3 fold increase in dose is required in many cases 
375 [60, 85, 86], dose increase were required in 80 % of the patients studied during pregnancy.  
376 5. CONCLUSIONS
377 The primary outcome of our work is that quetiapine doses as high as 1400 mg/day may be 
378 required during gestation, which is supported by case reports and clinical studies demonstrating 
379 few adverse clinical effects when using at doses of in excess of 800 mg/day.
380 For the first time, through the implementation of virtual clinical trials analysis, we have 
381 demonstrated that the reduction in quetiapine plasma concentrations are driven by both 
382 alterations in tissue physiology and the impact this has on the overall Vss, in addition to 
383 variation in CYP 3A4 abundance changes during gestation.  However, for other antipsychotics, 
384 this phenomenon would largely depend upon the gestational changes in specific CYP isozymes.  
385 For example, clozapine metabolic clearance is primarily mediated by CYP 1A2, which itself 
386 can undergo significant decreases in pregnancy.  
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387 Further studies are required to assess both the extent of this gestational change on plasma 
388 concentrations but also to also better identify a potential therapeutic range to better optimise 
389 any necessary dose adjustments.  However, we believe this study will provide a pragmatic basis 
390 with which to consider dose adjustment throughout gestation.
391
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647 Data represents mean (Standard deviation). a Calculated for current dosing period.
Study Sampling day Cmax (ng/mL) tmax (h) AUC (ng/mL.h) a
Predicted 42.53 (25.32) 1 (0.23) 144.29 (97.29)Day 1 
Observed 45 1.25 181
Predicted 123.02 (27.76) 1.28 (0.29) 1002.99 (409.18)Day 6 
+Ketoconazole Observed 150 1.25 1123
Predicted 663.42 (405.11) 1 (0.23) 2784.12 (2317)Day 9
Observed 1042 1.5 4650
Predicted 320.61 (131.19) 0.93 (0.22) 1137 (650.54)
Grimm[40]
Day 34 
+Carbamazepine Observed 205 1.3 621
Predicted 765.48 (339.7) 1 (0.22) 3168.82 (1673.07)Day 8
Observed 1048 (363) 1.4 (0.5) 3642 91375)
Predicted 439.01 (267.12) 0.94 (0.21) 1414.03 (1167.38)
Wong[41]
Day 8                               
+Phenytoin Observed 359 (328) 1.13 (0.36) 728 (445)
Potkin [42] Predicted 1032.71(50) 0.98 (0.65-1.40) 4223.86 (61)Day 21
Observed 1124.6 (31.9) 1.23 (0.5-3) 4508.9 (39.8)
Page 23 of 30 Journal of Pharmacy and Pharmacology
24
648 Table 2: Trough plasma quetiapine concentration during pregnancy
 
Baseline 
a T1 T2 T3
 (ng/mL)
Median 59.47 28.07 24.94 26.43
Mean 54.59 39.12 34.66 36.74
SD 26.98 29.09 25.26 26.41
SEM 4.61 6.20 5.38 5.63
CI high 47.71 46.82 41.39 44.18
CI low 31.09 22.16 19.96 21.23
Change (%) b 52.81 58.06 55.53
649
650 T1-T3 refers to each trimester; Data calculated from mid-point of each trimester; CI: 
651 confidence interval; SD: Standard deviation; SEM: standard error of the mean. a Baseline 




656 Table 3: Percentage of subjects with quetiapine trough concentrations greater than 50 
657 and 100 ng/mL
Dose Adjustment (mg)
50 ng/mL lower limit 100 ng/mL lower limit
Week Baseline 100 300 500  Baseline 100 300 500
5 34 66 86 98 14 24 55 81
10 28 58 82 97 9 21 43 73
15 25 48 75 96 6 19 34 69
20 24 45 72 95 4 18 33 65
25 24 44 72 95 4 16 32 63
30 24 45 74 95 4 18 33 62
35 28 54 81 96 9 20 38 68
38 31 60 83 96  12 22 44 69
658 Data calculated from day 1 of each week; Baseline represents non-pregnant females.
659
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660 LIST OF FIGURES
661
662 Figure 1:  Simulated quetiapine plasma concentrations during gestation
663 Simulated quetiapine plasma concentrations were generated during gestation using the Simcyp 
664 Pregnancy population group, with the population group (n=33) redefined on a daily basis to 
665 update study group physiology during gestation. Simulated concentrations represent post-dose 
666 (trough concentrations) sampled 10 hours after dosing. Subjects were administered a 200 mg 
667 twice daily dose (dose escalated from 25 mg twice daily over 1 week).  ‘Baseline’ refers to 
668 non-pregnant females.  Simulated concentrations represent post-dose (trough concentrations) 
669 sampled 10 hours after dosing and collated at 5-week intervals over the gestation period.  Red 
670 open circles represent observed (pooled) plasma concentrations obtained from a total of 33 
671 subjects. Black open circles present simulated plasma concentrations.
672
673 Figure 2: Impact of physiological alterations during pregnancy on quetiapine 
674 pharmacokinetics
675 Changes in quetiapine (A) clearance, (B) volume of distribution and (C) unbound fraction in 
676 plasma at baseline (non-pregnant females) and during gestation. Gestational week is indicated 
677 by GW. Box-plots ideates range (upper and lower bars) with calculation of median and 25th/75th 
678 percentiles. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
679
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680 Figure 3: Impact of alterations in Kp and CYP 3A4 abundance during pregnancy on 
681 quetiapine plasma concentrations 
682 (A) The impact of changes in Kp scalar and CYP 3A4 hepatic abundance on quetiapine 
683 plasma concentrations following multiple 200 mg oral doses (12-hourly).  Solid lines 
684 represent fixed CYP 3A4 abundance but increasing Kp scalar, with dashed lines representing 
685 changes in Kp scalar but fixed CYP 3A4 abundance.  (B) A sensitivity analysis comparing 
686 the impact of variation in Kp scalar (1 to 3) and CYP 3A4 abundance (137 to 180 pmol/mg 
687 protein) on final dose trough plasma concentrations in non-pregnant (red) and GW10 to 30.
688
689 Figure 4: Dose optimisation of quetiapine during gestation
690 The impact of dose escalation on median quetiapine plasma concentrations during gestation. 
691 Box-plots indicate range (upper and lower bars) with calculation of median and 25th/75th 
692 percentiles.   Baseline dose was 200 mg twice daily with escalation indicated as the additive 
693 increase in dose from baseline.  Dark shaded region indicates the proposed therapeutic 
694 window (100-500 ng/mL) with the lighter shaded region (50-100 ng/mL) indicating the 
695 proposed ‘extended’ range of the therapeutic window. 
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